PAREXEL International Corporation (PRXL) Shares Bought by Seven Eight Capital LP

Seven Eight Capital LP boosted its position in PAREXEL International Corporation (NASDAQ:PRXL) by 30.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,987 shares of the medical research company’s stock after purchasing an additional 11,500 shares during the period. Seven Eight Capital LP owned about 0.10% of PAREXEL International Corporation worth $4,257,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in PAREXEL International Corporation by 22,876.6% in the first quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares during the last quarter. Credit Suisse AG lifted its stake in PAREXEL International Corporation by 1,897.2% in the first quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after purchasing an additional 1,988,488 shares during the last quarter. State Street Corp lifted its stake in PAREXEL International Corporation by 2.1% in the first quarter. State Street Corp now owns 1,673,118 shares of the medical research company’s stock valued at $105,586,000 after purchasing an additional 34,328 shares during the last quarter. Nomura Holdings Inc. lifted its stake in PAREXEL International Corporation by 189.6% in the first quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock valued at $87,088,000 after purchasing an additional 904,236 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its stake in PAREXEL International Corporation by 9.8% in the first quarter. Clearbridge Investments LLC now owns 1,118,312 shares of the medical research company’s stock valued at $70,577,000 after purchasing an additional 99,758 shares during the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “PAREXEL International Corporation (PRXL) Shares Bought by Seven Eight Capital LP” was published by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/09/12/parexel-international-corporation-prxl-shares-bought-by-seven-eight-capital-lp.html.

PAREXEL International Corporation (PRXL) traded up 0.08% during mid-day trading on Tuesday, hitting $87.92. 466,932 shares of the stock were exchanged. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.95. The firm has a market capitalization of $4.46 billion, a price-to-earnings ratio of 42.68 and a beta of 0.79. The company’s 50-day moving average price is $87.65 and its 200 day moving average price is $77.08.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. During the same period in the prior year, the firm posted $0.94 EPS. Equities research analysts expect that PAREXEL International Corporation will post $3.95 EPS for the current year.

Several equities analysts recently commented on PRXL shares. Evercore ISI upgraded PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Monday, May 15th. Goldman Sachs Group, Inc. (The) upgraded PAREXEL International Corporation from a “sell” rating to a “neutral” rating and upped their price objective for the company from $63.00 to $77.00 in a research note on Tuesday, May 23rd. Barclays PLC reiterated an “overweight” rating and issued a $87.00 price objective on shares of PAREXEL International Corporation in a research note on Wednesday, May 17th. Credit Suisse Group reiterated a “neutral” rating and issued a $83.00 price objective (up previously from $65.00) on shares of PAREXEL International Corporation in a research note on Tuesday, June 6th. Finally, Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price objective on the stock in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $75.92.

PAREXEL International Corporation Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply